Chemo combo promising for pancreatic neuroendocrine tumors

July 13, 2012
Chemo combo promising for pancreatic neuroendocrine tumors
The combination of temozolomide and bevacizumab seems to benefit patients with advanced pancreatic neuroendocrine tumors, according to a study published online July 9 in the Journal of Clinical Oncology.

(HealthDay) -- The combination of temozolomide and bevacizumab seems to benefit patients with advanced pancreatic neuroendocrine tumors (NETs), according to a study published online July 9 in the Journal of Clinical Oncology.

Jennifer A. Chan, M.D., M.P.H., from the Dana-Farber Cancer Institute in Boston, and colleagues conducted a phase II study in which they treated 34 patients with NETs (56 percent carcinoid; 44 percent pancreatic NETs) with in combination with bevacizumab.

The researchers found that the combination of temozolomide and bevacizumab correlated with expected grade 3 to 4 toxicities, including lymphopenia (53 percent) and thrombocytopenia (18 percent). The radiographic response rate was 15 percent overall, and was 33 percent for patients with pancreatic NETs, compared with 0 percent for those with carcinoid tumors. Progression-free survival was a median of 11.0 months (14.3 months for pancreatic NETs versus 7.3 months for carcinoid tumors). Overall survival was a median of 33.3 months (41.7 months for pancreatic NETs versus 18.8 months for carcinoid tumors).

"Temozolomide and bevacizumab can be safely administered together in patients with advanced NETs, and the combination regimen appears promising for patients with pancreatic NETs," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including and Schering-Plough/Merck, which funded the study and manufacture bevacizumab and temozolomide.

Explore further: Adding erlotinib to bevacizumab/chemoradiotherapy regimen for pancreatic cancer safe, tolerable

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Adding erlotinib to bevacizumab/chemoradiotherapy regimen for pancreatic cancer safe, tolerable

June 19, 2012
The addition of high doses of erlotinib to the treatment regimen of bevacizumab and capecitabine with radiotherapy seems to benefit patients with locally advanced pancreatic cancer, according to results of a phase I study ...

ASCO: Continuing avastin with 2nd-line chemo ups survival

June 5, 2012
(HealthDay) -- Continuing use of bevacizumab (Avastin) in combination with second-line chemotherapy improves overall survival (OS) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) who ...

Researchers validate staging classifications for neuroendocrine pancreatic tumor surgery response

April 3, 2012
Researchers at Moffitt Cancer Center have carried out a study to validate the utility of new tumor classification systems for staging and predicting relapse-free survival for patients with neuroendocrine tumors (NETs) and ...

Bevacizumab active in HIV-linked Kaposi's sarcoma

March 20, 2012
(HealthDay) -- For patients with HIV-associated Kaposi's sarcoma (HIV-KS), bevacizumab is tolerated and induces a response in some patients, according to a study published online March 19 in the Journal of Clinical Oncology.

Pancreatectomy OK without downstaging from therapy

May 25, 2012
(HealthDay) -- Pancreatectomy improves median survival in pancreatic cancer patients even when presurgical neoadjuvant therapy does not lead to radiographic downstaging of tumors, according to a study published online May ...

Bevacizumab doesn't up overall survival in prostate cancer

March 27, 2012
(HealthDay) -- For men with metastatic castration-resistant prostate cancer (mCRPC), the addition of bevacizumab (B) to docetaxel plus prednisone (DP) is not associated with improved overall survival (OS), but does improve ...

Recommended for you

Researchers pinpoint causes for spike in breast cancer genetic testing

October 20, 2017
A sharp rise in the number of women seeking BRCA genetic testing to evaluate their risk of developing breast cancer was driven by multiple factors, including celebrity endorsement, according to researchers at the University ...

Study shows how nerves drive prostate cancer

October 19, 2017
In a study in today's issue of Science, researchers at Albert Einstein College of Medicine, part of Montefiore Medicine, report that certain nerves sustain prostate cancer growth by triggering a switch that causes tumor vessels ...

Gene circuit switches on inside cancer cells, triggers immune attack

October 19, 2017
Researchers at MIT have developed a synthetic gene circuit that triggers the body's immune system to attack cancers when it detects signs of the disease.

One to 10 mutations are needed to drive cancer, scientists find

October 19, 2017
For the first time, scientists have provided unbiased estimates of the number of mutations needed for cancers to develop, in a study of more than 7,500 tumours across 29 cancer types. Researchers from the Wellcome Trust Sanger ...

Researchers target undruggable cancers

October 19, 2017
A new approach to targeting key cancer-linked proteins, thought to be 'undruggable," has been discovered through an alliance between industry and academia.

Suicide molecules kill any cancer cell

October 19, 2017
Small RNA molecules originally developed as a tool to study gene function trigger a mechanism hidden in every cell that forces the cell to commit suicide, reports a new Northwestern Medicine study, the first to identify molecules ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.